Y-BIOLOGICS

Y-Biologics is Korea’s leading R&D biotech company in the field of antibody drug development.

Since establishing Y-Biologics in 2007, our company has focused on the research and development of antibody therapeutics, successfully building two main platform technologies: Ymax®-ABL, a unique human antibody library, and ALiCE, a novel format for bispecific T-cell engager antibodies.

Utilizing our excellent and differentiated platform technologies, we are striving to become a leading global antibody drug development company in the field of immuno-oncology.
Exploring Antibodies,
Creating Novel Therapeutics

Here at Y-Biologics, with our full-cycle antibody development capabilities, we are pursuing full-fledged development of
immuno-oncologic drugs using our bispecific antibody platform.

We aim to address unmet medical needs by developing a next-generation immunotherapeutics with higher patient response rates and superior efficacy in comparison to existing immuno-oncology drugs.

“Antibody Discovery Technology + Bispecific T Cell Engager Platform: To gain a strong foothold in the market for novel antibody therapeutics, which has high barriers to entry, we have set our focus on establishing platform technologies capable of discovering top-tier antibody drug candidates. This has led to the successful development of our globally competitive human antibody library and novel bispecific antibody format, a next-generation immunotherapy technology. Through these technologies, we are continuously developing a strong pipeline of novel immuno-oncology drugs with excellent efficacy.

“A Leader of Next-generation Immuno-oncology Therapeutic Development Based on our Antibody Platform Technologies: At Y-Biologics, we aim to set our proprietary platform technologies and pipelines apart from those of competitors in the field of antibody therapeutics, regarded as the future of pharmaceutical development, and emerge as a leading developer of novel antibody therapeutics contributing to improving the health of patients in Korea as well as the wider global society.